A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent<i>Clostridium difficile</i>Infection

2016316 citationsJournal Articlebronze Open Access

Authors

Sahil Khanna · Mayo Clinic

Darrell S. Pardi · Mayo Clinic

Colleen Kelly · Miriam Hospital

Colleen S. Kraft · Emory University

Tanvi Dhere · Emory University

Matthew R. Henn · Seres Therapeutics (United States)

Mary-Jane Lombardo ·

Abstract

SER-109 successfully prevented CDI and had a favorable safety profile, supporting a novel microbiome-based intervention as a potential therapy for recurrent CDI.

Topics & Keywords

Clostridium difficile and Clostridium perfringens research Gut microbiota and health Gastrointestinal motility and disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Journal of Infectious Diseases

Volume 214, Issue 2, pp. 173-181

DOI: 10.1093/infdis/jiv766

Field-Weighted Citation Impact: 31.89